Minoxidil

What it is

Minoxidil is one of only two Health Canada–approved medications for androgenetic alopecia (pattern hair loss), producing measurable regrowth in approximately 60% of users after 6–12 months of continuous use. Also sold under the brand name Rogaine — and in Canada under generics including Apo-Gain, Hairgro, and Minox — minoxidil is available as a 2% or 5% topical solution or foam, and increasingly as a low-dose oral tablet (0.25–5 mg/day) prescribed off-label by Canadian clinicians. Androgenetic alopecia (pattern hair loss) affects roughly 50% of men by age 50 and up to 40% of women over their lifetime, making minoxidil one of the most widely used medications in hormone-adjacent dermatology.

Causes and mechanism

Minoxidil was originally developed as an oral antihypertensive in the 1970s; scalp hair growth was observed as a side effect, leading to its topical reformulation. Its precise mechanism in hair follicles is still not fully understood, but three pathways are well-supported:

1. Potassium-channel opening — Minoxidil sulfate (the active metabolite, produced by sulfotransferase enzymes in the scalp) opens ATP-sensitive potassium channels in follicle smooth muscle, increasing local blood flow and oxygen delivery.
2. Follicle cycle prolongation — It extends the anagen (active growth) phase and shortens telogen (resting) phase, increasing the proportion of follicles actively producing hair.
3. Androgen receptor modulation — A 2014 study in Oncotarget (Hsu et al., PMC4039155) found that minoxidil suppresses androgen receptor transcriptional activity and reduces expression of androgen-regulated genes in prostate cancer cell lines. A 2023 study in Drug Design, Development and Therapy (Shen et al., PMC10461613) identified two additional enzymatic targets — CYP17A1 and CYP19A1 — suggesting minoxidil may alter steroidogenic pathways relevant to androgenetic alopecia. These findings are preliminary and have not yet changed clinical prescribing guidelines.

The sulfation step is rate-limiting: individuals with low scalp sulfotransferase activity respond poorly to topical minoxidil, which partly explains variable treatment outcomes.

Symptoms and diagnosis

Minoxidil is used to treat, not diagnose, hair loss. Before starting treatment, clinicians typically assess:

Hair loss type	Typical presentation	Minoxidil evidence
Androgenetic alopecia (male)	Bitemporal recession, vertex thinning	Strong; 5% solution/foam first-line
Androgenetic alopecia (female)	Diffuse crown thinning, preserved hairline	Strong; 2% or 5% solution approved
Alopecia areata	Patchy, non-scarring loss	Moderate; used adjunctively
Telogen effluvium	Diffuse shedding, often post-stress	Limited; may shorten duration
Scarring alopecias	Follicle destruction with fibrosis	Insufficient evidence

A dermatologist or family physician in Canada can diagnose pattern hair loss clinically; trichoscopy or scalp biopsy is reserved for atypical presentations. LifeLabs and Dynacare both offer hormone panels (testosterone, DHEA-S, TSH, ferritin) to rule out secondary causes before attributing hair loss to androgenetic alopecia.

Treatment options

Topical minoxidil remains the standard starting point. The 5% concentration outperforms 2% in head-to-head trials, including in women, though the 2% formulation is the only concentration with a formal Health Canada indication for female-pattern hair loss. Foam formulations reduce scalp irritation from propylene glycol found in solutions.

Oral minoxidil (0.25–5 mg/day) is prescribed off-label in Canada for patients who find topical application inconvenient or who have low scalp sulfotransferase activity. A 2022 systematic review in the Journal of the American Academy of Dermatology found oral minoxidil effective at doses as low as 0.25 mg/day in women, with a favourable side-effect profile at low doses.

Combination therapy with finasteride (men) or spironolactone (women) is common in clinical practice. Finasteride blocks DHT production; minoxidil acts independently of the androgen axis, so the two are complementary. Canadian online prescribing platforms — including Felix, Maple, and others — offer minoxidil-containing hair-loss programs, though patients with complex presentations should see a dermatologist in person.

Key practical points:

• Visible results typically require 4–6 months; full assessment at 12 months.
• Shedding in the first 4–8 weeks is normal (telogen effluvium from follicle cycling) and not a reason to stop.
• Hair loss resumes within 3–6 months of discontinuation; minoxidil does not alter the underlying genetic predisposition.

When to see a clinician in Canada

See a family physician or dermatologist if: hair loss is rapid or patchy (may indicate alopecia areata or a systemic cause); you are a woman with signs of androgen excess (irregular periods, acne, hirsutism — possible PCOS or adrenal disorder); you have cardiovascular disease or are on antihypertensives (oral minoxidil requires blood pressure monitoring); or topical minoxidil has produced no response after 12 months of consistent use.

Oral minoxidil requires a prescription in Canada. Topical 2% and 5% formulations are available over the counter at most pharmacies. Provincial drug benefit plans (e.g., Ontario's ODB, BC PharmaCare) generally do not cover minoxidil for cosmetic hair loss, though coverage may apply when hair loss is secondary to a covered medical condition — confirm with your provincial formulary.

Limitations and open questions

Research is still emerging on several fronts. The precise contribution of androgen receptor suppression and CYP enzyme modulation to minoxidil's clinical effect in humans has not been established; the 2014 and 2023 mechanistic studies were conducted in cell lines or used computational modelling, not clinical trials. The optimal dose and duration of oral minoxidil, particularly in women and non-binary patients, lacks large randomized controlled trial data. Long-term cardiovascular safety of low-dose oral minoxidil in otherwise healthy individuals has not been studied in trials exceeding two years. Health Canada has not issued updated guidance specifically addressing oral minoxidil for alopecia, leaving prescribers to rely on off-label consensus and international dermatology society statements. Individual response variation linked to sulfotransferase enzyme activity is clinically meaningful but not yet routinely tested in Canadian practice.